Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy.


*These authors contributed equally.
**These authors contributed equally.

1 University of Cambridge Metabolic Research Laboratories, Wellcome Trust–Medical Research Council Institute of Metabolic Science, University of Cambridge, UK.
2 Diabetes and Obesity Research Program, Garvan Institute of Medical Research, Sydney, Australia.
3 Wellcome Trust Sanger Institute, Hinxton, University of Cambridge, UK.
4 Institute of Endocrinology and Diabetes, The Children’s Hospital at Westmead, Australia.
5 Discipline of Paediatrics and Child Health, University of Sydney, Australia.
6 CSIR-IGIB, Sukhdev Vihar, Mathura Road, New Delhi, India.
7 Diabetes Centre and Department of Endocrinology, St Vincent’s Hospital, Sydney, Australia.
8 Current PhD Student at Kolling Institute of Medical Research, University of Sydney, Australia.

Corresponding authors:
Dr D.B. Savage or Prof. L. Campbell
Metabolic Research Laboratories, or Diabetes and Obesity Research Program,
Institute of Metabolic Science, Garvan Institute of Medical Research
Univ. of Cambridge, 384 Victoria St, Darlington
Addenbrooke's Hospital, Hills Road, NSW 2010, Australia
Cambridge CB2 0QQ, UK Tel: +61 292958231
Tel: +44 1223 767923 Fax: +61 292958235
Fax: +44 1223 330 598 Email: l.campbell@garvan.org.au
Email: dbs23@medschl.cam.ac.uk

Conflict of interest: The authors have declared that no conflict of interest exists.

Word count: 4077, Figures: 7, Table: 1, Online Supplementary Figure: 2
Abstract

Perilipin-1 is a lipid droplet coat protein predominantly expressed in adipocytes, where it inhibits basal and facilitates stimulated lipolysis. Loss-of-function mutations in PLIN1 were recently reported in patients with a novel subtype of familial partial lipodystrophy, designated as FPLD4. We now report the identification and characterization of a novel heterozygous frameshift mutation affecting the carboxy-terminus (439fs) of perilipin-1 in two unrelated families. The mutation co-segregated with a similar phenotype including partial lipodystrophy, severe insulin resistance and type 2 diabetes, extreme hypertriglyceridaemia and non-alcoholic fatty liver disease in both families. Poor metabolic control despite maximal medical therapy prompted two patients to undergo bariatric surgery, with remarkably beneficial consequences. Functional studies indicated that expression levels of the mutant protein were lower than wild type protein and in stably transfected pre-adipocytes the mutant protein was associated with smaller lipid droplets. Interestingly, unlike the previously reported 398 and 404 frameshift mutants, this variant binds and stabilizes ABHD5 expression, but still fails to inhibit basal lipolysis as effectively as wild type perilipin-1. Collectively, these findings highlight the physiological need for exquisite regulation of neutral lipid storage within adipocyte lipid droplets, as well as the possible metabolic benefits of bariatric surgery in this serious disease.
Introduction

Adipocytes within white adipose tissue are uniquely adapted to storing large quantities of triglyceride in a single unilocular lipid droplet, providing a highly economical mechanism for surplus energy storage. Perilipin-1 is the most abundant phosphoprotein in adipocytes, where it constitutively associates with the phospholipid surface monolayer of the lipid droplet [1]. Here it regulates lipases, particularly adipose tissue triglyceride lipase (ATGL) and hormone sensitive lipase (HSL). ATGL and HSL catalyze the sequential hydrolysis of tri- and then di-acylglycerol, releasing fatty acids and monoacylglycerol which undergoes a final hydrolytic cleavage step by monoacylglycerol lipase (MGL) [2]. Precise regulation of this process is a major factor in determining the efficacy of adipose tissue as a lipid buffer in the fed state and then subsequently as a source of lipid fuel in the fasting state or during exercise.

The importance of perilipin-1 function in human metabolism was very recently highlighted by the discovery of two heterozygous PLIN1 frameshift mutations affecting the C-terminus of the protein in patients with FPLD4 [3]. Both mutations co-segregated with partial lipodystrophy, severe insulin resistance, hepatic steatosis and severe dyslipidaemia in three French families. Molecular characterization of these mutations demonstrated the inability of both mutants to inhibit basal lipolysis. In each case this was attributable to the failure of the proteins to effectively prevent ABHD5 (αβ-hydrolase domain containing 5), a co-activator of ATGL, from activating ATGL and thus increasing basal lipolysis [4]. Here we report the identification, clinical characterization and functional analysis of a third PLIN1 heterozygous mutation.
**Experimental procedures**

**Genetic analysis**

The study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the UK National Health Service Research Ethics Committee. Each participant, or a parent in the case of minors, provided written informed consent; minors provided oral consent.

Genomic DNA was isolated from peripheral-blood leukocytes. After excluding mutations in the coding regions and splice junctions of LMNA and PPARG, the coding regions and splice junctions of PLIN1 were amplified by PCR and sequenced as described previously [3].

**Clinical and biochemical studies**

Blood samples for biochemical assays were taken after an overnight fast. Patients underwent skin fold measurements using calipers; results were expressed as the mean of two independent measurements and compared to previously reported reference ranges [5]. Dual energy X-ray absorptiometry (DEXA) (Lunar Prodigy DXA scanner, software version 12.20) was used to evaluate body composition.

**Cloning strategy**

Site-directed mutagenesis was performed on pCR-BluntII-TOPO PLIN1 WT [3] using QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) to generate the PLIN1 p.Pro439ValfsX12 (from here onwards referred to as PLIN1 439fs) mutant using the following set of primers 5’-CGGAGGCGCAGAGCGTCGGGCGCCGTCCGCCGG-3’ and 5’-CCGGCGGACGCGCCGCCGACGCTCTGCGCTCCG-3’. For the generation of stable cell lines, a N-terminally Myc-tagged PLIN1 439fs mutant sequence was subcloned using SalI.
restriction enzyme sites into the retroviral expression vector pBABEpuro (Clontech) harboring a puromycin resistance cassette. For transient transfections the same sequence was subcloned into pcDNA3.1 vector using EcoRV-XbaI restriction sites. For bimolecular fluorescence complementation (BiFC) assays, pcDNA 3.1 mycPLIN1-439fs-Yc was cloned in frame with the C-terminal Yc fragment in previously generated pcDNA3.1-Yc using EcoRV-BplI [4]. The following constructs pcDNA3.1-Yc, pcDNA3.1-Yn, pcDNA3.1-YN-hABHD5, pcDNA3.1-hATGL(S47A)-Yc and pcDNA3.1-MycPLIN1-398fs-Yc were previously generated as described in [3, 4].

**Cell culture**

Stable cell lines were generated and maintained as described in [3]. In order to study the effects of PLIN1 439fs in the presence of WT perilipin-1, a previously described 3T3-L1 pre-adipocyte stable cell line expressing pLXSN-Flag-PLIN1-WT [3] was subjected to a second round of retrovirus transduction with pBABEpuro-myc-PLIN1-WT or mutants.

**qRT-PCR**

mRNA was harvested and extracted using a RNeasy Mini Kit (QIAGEN). cDNA synthesis was performed using the Superscript II reverse transcriptase enzyme (Invitrogen). Quantitative real time-PCR was performed using an ABI TaqMan master mix according to the manufacturer’s protocols. The following primer sets were used: hPLIN1 (forward, 5’-CCCCCTGAAAAAGATTGCTTCTTCT-3’; reverse, 5’-GGAACGCTGATGCTGTTTCTG-3’; probe, 5’FAM-CATCTCCACCCGCCTCCGCA TAMRA-3’), PPIA (forward, 5’TTCCTCCTTTTACAGAATTATATCCA-3’; (reverse, 5’- CCGCCAGTGCCATTATGGG-3’; probe, 5’FAM- 6ATTCCATGTGCCAGGGTGTTACACTTTACAC-TAMRA-3’). Results
were analysed on an ABI PRISM 7900HT (Applied Biosystems) and normalized to housekeeping gene (Cyclophilin A) expression levels.

**Western Blotting**

For patient adipose tissue protein expression analysis, tissue was homogenized in liquid nitrogen and directly lysed in RIPA buffer (SIGMA) containing protease and phosphatase inhibitors (Roche). Protein was quantified using Bio-Rad DC protein quantification kit and 10 µg of protein lysate was diluted in NuPAGE 4xLDS sample buffer (Invitrogen) containing 0.05% β-mercaptoethanol and subjected to SDS-PAGE, following transfer onto a nitrocellulose membrane. Following transfer, membranes were washed in Tris-buffered saline containing 0.1% TWEEN-20 (TBS-T; Sigma-Aldrich), then blocked for 1 hour at room temperature (RT) in 3% bovine serum albumin (BSA) or 5% powdered skimmed milk diluted in TBS-T. Membranes were further incubated with appropriate primary antibody diluted in blocking buffer for 16 hours at 4°C. The following antibodies were used: Perilipin-1 N-terminal antibody (GP29, Progen), Perilipin-1 C-terminal antibody (Abcam), Perilipin-2 (GP40, Progen) Myc (Milipore), Flag (Sigma), ABHD5 (Abnova), Calnexin (Abcam) or β-actin (Abcam). For cellular protein extracts 50 µg of lysate was subjected to SDS-PAGE.

**Estimation of protein degradation**

3T3-L1 pre-adipocytes stably expressing either WT or 439fs perilipin-1 were grown until confluence and treated with either DMSO as a control or 100 µg/ml cycloheximide, 10 µM MG132 and 25 mM NH₄Cl for indicated times before lysis.

**Microscopy studies**
For microscopy studies, cells were seeded into 12-well plates containing slides previously rinsed in 70% ethanol. Cells were harvested by rinsing 3 times in PBS and fixing with 4% formaldehyde diluted in PBS for 15 minutes (min) at RT. Membrane permeabilisation was achieved with 0.5% Saponin for 10 min, followed by blocking in 3% BSA, 0.05% Tween-20 PBS for 1 hour. Afterwards cells were incubated with primary antibody diluted in blocking buffer for 16 hours at 4°C. Then cells were washed 3 times in 0.1% BSA PBS and incubated with fluorescent probe conjugated secondary antibody for 1 hour at RT wrapped in foil. Where necessary, cells were stained for neutral lipid, by rinsing 3 more times with 0.1% BSA-PBS and adding LipidTox Deep Red reagent (Invitrogen) diluted in PBS [1:1000] for 20 min at RT. Afterwards cells were rinsed in PBS and slides mounted using ProLong Gold antifade mounting reagent with DAPI (Invitrogen) for nuclear staining.

*Lipid droplet volume measurements*

3T3-L1 pre-adipocytes were treated with 400 μM oleic acid (Sigma) for 48 hours and harvested for microscopy studies as described above. LipidTox Deep Red was used to stain neutral lipids within lipid droplets, and anti-Myc primary antibody [1:500] dilution in 3% BSA, followed by goat anti-mouse Alexa-Fluor-488 fluorescent secondary antibody was used for perilipin-1 staining. Cell imaging was performed on a Zeiss LSM 510 Meta confocal microscope using the Zen software package (Carl Zeiss Microimaging GmbH). On average 10 Z-stack images were taken per sample using the 63x objective and lipid droplet volume was measured using Volocity 5 software (Perkin Elmer).

*Lipolysis*
Lipolysis experiments were performed as described in [4] in the presence of 6 µM Triascin C in order to prevent fatty acid re-esterification. Lipolysis was expressed as a ratio of the amount of radioactivity released into the medium over the total amount of incorporated radioactivity.

**Bimolecular Fluorescence complementation (BiFC)**

BiFC experiments and signal quantification were performed in cos 7 cells as described in [4, 6]. In cells expressing perilipin-1 (WT or mutants), ATGL(S47A)-Yc and ABHD5-Yn, total YFP signal was normalised to control cells only expressing ATGL(S47A)-Yc and ABHD5-Yn. All components were normalized for equal protein expression in these experiments.

**Statistical analysis**

Quantitative data are presented as mean ± SEM. One-way or two-way analysis of variance with post hoc Bonferroni analyses were performed on data at a minimum P<0.05.
Results

Case studies

Proband A, a 41-year old Caucasian woman (Figure 1A, I.1), was referred to specialist physicians in Sydney in 1998 with a ten year history of type 2 diabetes, complicated by diabetic retinopathy, extreme hypertriglyceridaemia leading to recurrent pancreatitis, non-alcoholic fatty liver disease (NAFLD; visualized on ultrasound and CT (computerized tomography)) and hypertension. She also had new-onset exercise intolerance (exertional dyspnea without chest pain) and muscle cramping. Her diabetes was suboptimally controlled despite high dose insulin therapy (>500 units daily). Insulin resistance was confirmed by a hyperinsulinaemic-euglycaemic clamp (glucose infusion rate 10.6 µm/min/kg fat free mass). The patient had no history of polycystic ovarian syndrome (PCOS) and no difficulty conceiving as is apparent from 4 successful pregnancies. Her first pregnancy was uncomplicated but her second child was delivered early because of large size for gestational age. The diagnosis of diabetes was made after her third pregnancy.

Her BMI was 31.2 kg/m² and waist circumference 93 cm. Lipoatrophy was most notable in the femorogluteal depot and lower limbs, with abdominal fat largely preserved (Supplementary figure 1). Skin-fold measurements (Supplementary figure 2) confirmed excess subcutaneous truncal fat and reduced peripheral fat. In addition, DEXA scan (dual energy X-ray absorptiometry) confirmed disproportionate fat loss on the limbs (Table 1). Her cardiovascular and respiratory examinations were normal. There were no dysmorphic features.

Biochemical investigations revealed severe hypertriglyceridaemia and suboptimal glycemic control (Table 1). Her lipoprotein-a level was elevated at 680 mg/L (<300) and leptin level was low (Table 1). An echocardiogram revealed a reduced ejection fraction of 30% and a
coronary angiogram showed an occluded right coronary artery. Nerve conduction studies and electromyography were reported as normal, with only occasional small atrophic fibres. A deltoid muscle biopsy was normal.

The patient’s eldest daughter, now aged 38 (Figure 1A, II.1), was diagnosed with PCOS, dyslipidaemia, fatty liver disease (ultrasound), hypertension and type 2 diabetes at age 24 years. She was initially managed with metformin, but required >500 units/day of insulin during the later stages of her first pregnancy, during which she weighed up to 120kg (BMI 40.1 kg/m²). She has had four pregnancies, all of which were complicated by hypertension, necessitating hospital admission in two pregnancies. All four children are well and have not been tested for diabetes.

The proband’s oldest son (Figure 1A, II.2) has a lipodystrophic phenotype and a BMI of 29.1 kg/m² but has not been genetically tested or assessed for diabetes or dyslipidaemia. Her middle son (Figure 1A, II.3), aged 33, is centrally obese with a BMI of 39 kg/m², diabetes and mild hypertriglyceridemia. Her youngest son, aged 18 years (Figure 1A, II.4), has type 2 diabetes, managed with oral medication, and a BMI of 29.1 kg/m². The proband’s brother, aged 55 (BMI of 25.3 kg/m², Figure 1A, I.2), also has diabetes, a fat mass ratio (FMR) of 2.2 and skinfold measurements consistent with a lipodystrophic phenotype (Figure 1A).

In 2005, proband A underwent Roux-en-Y gastric bypass surgery in an effort to improve her glycaemic control and hypertriglyceridemia. This resulted in a 20 kg weight loss, substantial reduction in insulin requirements (from 500- to 100 units/day), improved lipid profile and reversal of cardiomyopathy on echoardiography. The patient’s daughter also underwent Roux-en-Y bypass surgery, resulting in a 55 kg loss of weight (BMI then 22.4 kg/m²), cessation of insulin, a subsequent twin birth and two further successful uncomplicated pregnancies. In the past 2 years, the proband has been diagnosed with a popliteal artery aneurysm, requiring surgical repair and vascular stenting. Her diabetes is currently treated
with a lower dose of insulin and a very low fat diet. Hypertriglyceridaemia is controlled with gemfibrozil and maxepa. Her echocardiogram is now within normal limits, with an ejection fraction increasing from 30% to 59%.

**Proband B**, an unrelated 15 year-old boy of Caucasian origin, presented with acanthosis nigricans, hepatomegaly and NAFLD (Figure 1A). His BMI was 25.1 kg/m$^2$ (SDS 1.51) with central adiposity (waist to height ratio 0.54, normal <0.5) and a striking paucity of limb fat. Biochemical investigations showed severe hypertriglyceridaemia with normal total cholesterol and low HDL cholesterol levels (0.4 mmol/L). An oral glucose tolerance test confirmed the presence of extreme insulin resistance. He had impaired glucose tolerance with a 2 hour glucose level of 10.7 mmol/L and an astonishing peak insulin level of 12,396 pmol/L. His leptin level was low (Table 1). Liver biopsy confirmed significant hepatic steatosis.

The patient’s mother had been diagnosed with PCOS, treated with metformin since age 25 years, and required in vitro fertilisation for her first pregnancy at age 28 years. She was subsequently diagnosed with type 2 diabetes requiring >200 units of insulin daily during pregnancy. She continued to have poor glycaemic control, microalbuminuria and NAFLD complicated by cirrhosis (on liver biopsy). Lipoatrophy was first recognised clinically in her early 40s affecting her limbs and buttocks, with mild central adiposity and prominent deltoid, gluteal and calf muscles. She had coarse facial features and androgenic alopecia. She was lean (BMI 21.8 kg/m$^2$) and her leptin level was low (Table 1). His father was obese (BMI 37 kg/m$^2$) with associated dyslipidaemia, but did not have features of severe insulin resistance (Figure 1A).
Identification of a novel PLIN1 p439fs mutation

Both probands were wild type for PPARG and LMNA gene sequencing. Candidate gene sequencing of all exons and splicing regions of the PLIN1 gene revealed a heterozygous deletion of two adjacent nucleotides (thymidine and guanine) within exon 9 (c.1298_1299delTG), resulting in a translational frameshift (Figure 1B). The mutation is predicted to lead to the incorporation of 125 aberrant amino acids from amino acid position 439 onwards, thus producing an elongated protein (563 amino acids rather than 522) (Figure 2A). The same mutation was present in both probands, although they are not known to be related. The mutation co-segregated with partial lipodystrophy, severe insulin resistance, severe dyslipidaemia and NAFLD in both kindreds (Figure 1A). Gestational hypertension was prominent in affected women.

Detection of the PLIN1 p439fs mutant protein in patient adipose tissue

In order to determine whether the frameshift perilipin-1 mutant protein is expressed in vivo, samples of both visceral abdominal and subcutaneous adipose tissue were obtained from Proband A (at the time of a medically indicated surgical procedure) and subjected to SDS-PAGE alongside subcutaneous fat samples from gender matched controls (Figure 2B). Both the wild type (WT) and 439fs copy of perilipin-1 are detectable with an N-terminal epitope targeted antibody, however the higher molecular weight band corresponding to the 439fs protein was not detected by an antibody which targets a C-terminal epitope. Notably, the levels of WT and particularly the 439fs protein were reduced in the patient compared to controls.

In addition, in both murine and cell models, a decrease in perilipin-1 expression levels in adipocytes is typically associated with up-regulation of perilipin-2 expression [7]. In
accordance with this, our patient manifested an increase in perilipin-2 expression in both visceral and subcutaneous adipose tissue when compared to controls (Figure 2B).

Functional characterization of the PLIN1 p439fs mutation

In order to functionally characterize the effects of the PLIN1 439fs mutation, 3T3-L1 pre-adipocytes were stably transfected with retroviral vectors expressing pBABEpuro PLIN1 WT or the PLIN1 398- or PLIN1 439 frameshift mutants, all bearing a N-terminal Myc tag. 3T3-L1 pre-adipocytes do not express endogenous perilipin-1, enabling us to directly compare their function in the absence of the potentially confounding influence of endogenous perilipin-1. The PLIN1 398 frameshift mutation was characterized in previous work and served as a ‘negative’ control in these studies [3]. All of the above mutant proteins are predicted to have a disordered C-terminus following the frameshift. In keeping with the patient biopsy findings, expression levels of the 439fs mutant were lower than those of the WT protein despite equivalent mRNA expression levels (Figure 3A,B). Expression of the 398fs mutant was even lower than that of the 439fs. In the presence of cycloheximide, the half-life of the 439fs protein was reduced compared to WT perilipin which is known to be particularly stable when associated with lipid droplets (Figure 3C,D)[8-10]. The fact that co-incubating the stable cell lines exposed to cycloheximide with a proteasomal inhibitor (MG132) modestly increased 439fs expression whereas the addition of a lysosomal inhibitor (NH₄CL) had no discernible affect (Figure 3E), suggests that the 439fs perilipin-1 mutant is probably degraded via the proteasome. We also noted that the addition of MG132 increased endogenous perilipin-2 expression, which has been previously shown to be degraded via the proteasome (Figure 3E), providing useful corroborative evidence for the efficacy and specificity of MG132 as a proteasomal inhibitor in these cells.
The perilipin-1 439fs mutant is associated with smaller lipid droplets

Since perilipin-1 is critical for lipid accumulation in adipocytes [11], we assessed the impact of expression of the 439fs mutant on lipid droplet size in 3T3-L1 fibroblasts. After 48 hours of exposure to medium containing oleic acid, perilipin-1 WT overexpressing cells accumulated several large lipid droplets, whereas cells expressing the perilipin-1 439fs mutant contained a more heterogeneous population of significantly smaller lipid droplets (Figure 4A, B). There was no difference in the ability of C-terminal perilipin-1 mutants to target to the lipid droplets (Figure 4A). Perilipin-1 has previously been shown to exert its effect on lipid accumulation primarily through the inhibition of basal lipolysis rather than an increase in triglyceride synthesis [12]. We thus hypothesized that the 439fs mutant may facilitate higher rates of basal lipolysis. In order to test this hypothesis, cells were incubated with oleic acid overnight, promoting lipid droplet accumulation, followed by a 4 hour chase period in the presence of Triacsin C to inhibit free fatty acid (FFA) re-esterification. Wild type (WT) perilipin-1 significantly suppressed FFA release, whereas the 439fs perilipin-1 mutant did so less effectively, albeit to a greater extent than the 398 perilipin-1 frameshift protein (Figure 4C).

Perilipin-1 439fs mutant is able to bind ABHD5

In an effort to reveal the molecular mechanisms underpinning the 439fs mutant’s failure to fully suppress basal lipolysis we employed Bimolecular Fluorescence Complementation (BiFC) assays to assess the interaction of the perilipin-1 439fs with ABHD5 (Figure 5). As both the 439- and 398fs mutants are expressed at lower levels than WT protein, expression plasmids were titrated in order to achieve equal protein expression. YFP signal was
reconstituted when ABHD5-Yn was expressed with either WT or the 439fs mutant, but not in the presence of the 398fs mutant, implying that the 439fs is still able to interact with ABHD5. This is in agreement with previous studies, where amino acids 382-429, equivalent to amino acids 380-427 in the human sequence of perilipin-1, were shown to be crucial for ABHD5 binding [13].

One could hypothesize that the conformational change induced by the C-terminal frameshift would allow the 439fs mutant to bind ABHD5, but might not necessarily prevent the subsequent interaction between ABHD5 and ATGL, as occurs with WT perilipin-1. We tested this hypothesis by assessing the ability of the 439fs perilipin-1 mutant to inhibit direct interaction between ABHD5 and ATGL. In this assay, expression of ATGL (S47A)-Yc and ABHD5-Yn results in bright YFP fluorescence which is reduced by ~70% when either WT or the 439fs perilipin-1 mutant is expressed (Figure 6). In contrast, expression of the 398fs mutant has no effect on the interaction between ATGL and ABHD5.

Expression of perilipin-1 WT does not rescue 439fs mutant phenotype

Finally, in an effort to mimic the in vivo consequences of the heterozygous mutation, the 439fs mutant was co-expressed with flag-tagged wild type perilipin-1 (WT). 439fs protein levels were stabilized to some extent by the expression of a WT copy of perilipin-1 (Figure 7A). The results suggest that increasing the amount of WT perilipin-1 protein increases lipid droplet volume (Figure 7C,D), whereas co-expression of either the 439fs or 398fs mutants fails to further increase lipid droplet volume. In accordance with these data, measurement of basal lipolysis in these cell lines showed less inhibition of basal lipolysis by the 439fs perilipin-1 mutant than WT perilipin-1 even in the presence of WT perilipin-1 (Figure 7E).
Discussion

Lipodystrophic syndromes are a rare, but fascinating cause of insulin resistant type 2 diabetes. The archetypal feature of all lipodystrophies is a lack of adipose tissue, which can either be partial or generalized. Nevertheless the consequences of lipodystrophy, which include dyslipidaemia, NAFLD, hyperandrogenism and PCOS in women and accelerated cardiovascular disease are remarkably similar to those usually associated with obesity as part of the metabolic syndrome [14]. This observation in itself constitutes a key piece of evidence underpinning the so called ‘lipid overflow hypothesis’ which posits that the capacity of mammalian adipose tissue to accommodate surplus lipid is finite, and that when this capacity is exceeded, lipids accumulate in ectopic sites, such as the liver and skeletal muscle where they are instrumental in causing insulin resistance [15].

Within the last 15 years several monogenic defects have been causally linked to human lipodystrophic syndromes, collectively advancing the understanding of human adipogenesis and adipocyte function, and the systemic metabolic consequences of ‘adipocyte dysfunction’ [16, 17]. More recently, our laboratory has reported the consequences of loss-of-function mutations in proteins implicated in the formation and functional regulation of adipocyte lipid droplets [3, 18]. Interestingly CIDEC and PLIN1 encode LD proteins almost exclusively expressed in white adipocytes emphasizing firstly their importance in determining the unique properties of adipocyte LDs and secondly the ‘whole organism’ consequences of dysfunction of proteins primarily expressed in adipocytes (perilipin-1 is also expressed in adrenal cells, and both proteins can be expressed in steatotic hepatocytes).

The original description of patients with FPLD4 due to PLIN1 mutations was based on a description of 6 affected subjects. In order to better understand this novel phenotype we have attempted to identify more affected subjects. These efforts enabled us to identify another two probands and four affected relatives with a different PLIN1 mutation (439fs) to those
previously reported. The key features of patients with the 439fs mutant include lack of peripheral fat depots, severe insulin resistance and extreme hypertriglyceridaemia. These features are consistent with what was observed in patients with either the PLIN1 398 or 404 frameshift mutations. The effect of bariatric surgery on the metabolic phenotype of Proband A was particularly striking. She experienced a 20 kg weight loss, with an 80% reduction in insulin requirements, improved lipid profile, reversal of cardiomyopathy and improvement in muscle strength. Her daughter exhibited a similar improvement in metabolic profile. These metabolic improvements are consistent with case reports describing the response to bariatric surgery in other forms of partial lipodystrophy [19-21] and highlight the importance of ‘relieving’ the energetic stress imposed upon their dysfunctional adipocytes. The beneficial symptomatic and functional effect of bariatric surgery on cardiac function in obese patients with cardiomyopathy has been described in a limited number of reports, but not yet in patients with lipodystrophy [22].

Functional studies of the 439fs mutant suggest that it is associated with smaller lipid droplets and higher basal lipolytic rates. These data are consistent with previously reported studies by Garcia et al, who observed less triglyceride accumulation in cells over-expressing an artificially generated perilipin-1 truncation mutant which truncates the protein at an amino acid very close to the site of our 439fs mutant, namely E427 stop [11]. However, understanding why the 439fs mutant is associated with higher basal lipolytic rates is more complex than was the case for the previously reported human mutants (398 and 404fs) as those fail to bind and stabilize ABHD5, whereas our studies suggest that the 439fs mutant does bind ABHD5, stabilize its expression and sequester it from ATGL. One possible explanation might be the strikingly reduced expression of the 439fs mutant, which was observed in tissue samples from Proband A and in transfected cells. The aberrant C-terminus of 439fs mutant protein is likely to be disordered, which would account for its propensity to
degradation as occurs with many mutant proteins [23]. Interestingly, even partial loss of perilipin-1 is sufficient to reduce fat mass as observed in Plin1 heterozygous knockout mice [7]. Absent perilipin-1 expression in Plin1 null mice was also associated with concomitant up-regulation of perilipin-2 [7, 24]. Thus the observed up-regulation of perilipin-2 expression in fat biopsies from Proband A provides further evidence for reduced total perilipin-1 expression in vivo. We cautiously conclude therefore that reduced perilipin-1 expression is likely to be an important factor in the phenotype observed in patients with the 439fs PLIN1 mutation. It is also very likely that the C-terminus of perilipin-1 has additional, as yet incompletely understood, biological functions which are likely to be impaired by this mutation.

In summary, we report the clinical and molecular characterization of a novel PLIN1 frameshift mutation in two kindreds with FPLD4. The severity of metabolic disease seen in affected patients further highlights the importance of precise lipolytic regulation in adipose tissue in human health. Finally, the highly beneficial response of two patients with this disorder to bariatric surgery emphasizes the importance of weight loss in these patients. Surgery lessens ectopic fat deposition and offers at least one useful management option for an otherwise devastating metabolic illness.
Author contributions

DBS designed the study in collaboration with SO’R and IB. VT, YHC, SS, and LC undertook clinical studies. WB, II and KK performed genotyping. KK performed functional studies. SG, MML, KL and SP assisted with functional studies. VS provided functional insight into the expected consequences of the mutation. KK, VT, SP, JRG, LC and DBS contributed to data analysis, discussion and wrote the manuscript. All authors reviewed and edited the manuscript. DBS and LC are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of data analysis.

Acknowledgements

We are very grateful to the patients who participated in these studies and to the medical staff who assisted in their management. This work was supported by grants from the Wellcome Trust (D.B.S, S.O’R, I.B.), the U.K. NIHR Cambridge Biomedical Research Centre, the MRC Centre for Obesity and Related Metabolic Disease and a BBSRC CASE studentship (K.K.).
References

Figure Legends

Figure 1. A heterozygous PLIN1 439fs mutation co-segregates with insulin-resistant diabetes, dyslipidemia and partial lipodystrophy. A) Family pedigrees of probands A and B showing co-segregation of p.Pro439ValfsX125 with insulin resistance, dyslipidemia, lipodystrophy and, to a lesser extent, hypertension. M1 denotes PLIN1 p.Pro439ValfsX125 mutation, N- wild type and ND- not determined. Probands are denoted by an arrow. B) Sequence chromatogram confirming deletion of a TG base pair within exon nine (nucleotide 1298) and the predicted consequences of this mutation on the amino acid sequence of perilipin-1.

Figure 2. Predicted consequences of the perilipin-1 439fs mutant and documentation of its expression in adipose tissue. A) A schematic representation of the expected effects of the perilipin-1 439fs mutation on the protein domain organisation. B) Immunoblots showing perilipin-1 and 2 expression in adipose tissue samples from proband A (these include a visceral fat and subcutaneous leg fat sample) compared with expression in subcutaneous abdominal fat samples from two control samples. The N-terminal perilipin-1 antibody (GP29) detects both mutant (arrow) and wild type perilipin-1, whereas the C-terminal antibody only detects wild type perilipin-1. Calnexin was used as a loading control.

Figure 3. Expression of the perilipin-1 439fs mutation in stably transduced 3T3-L1 pre-adipocyte cell lines. 3T3-L1 pre-adipocytes stably expressing either empty vector (EV) or N-terminally Myc tagged perilipin-1 wild type (WT), perilipin-1 439fs (439fs) and 398fs (398fs) mutants were generated as described in the materials and methods. A) Immunoblot analysis of perilipin-1 expression using an anti-Myc antibody, β-actin was used as a loading
control. **B)** mRNA levels of hPLIN1 normalized to mCyclophilinA expression. **C, D)** Stably transfected 3T3-L1 pre-adipocytes expressing WT and 439fs perilipin-1 were grown to confluency and treated with 100 µg/ml cycloheximide for the indicated times. Cells were lysed and perilipin-1 expression levels were detected by immunoblotting with anti-Myc antibody and β-actin to assess loading. **C)** A representative image is shown. **D)** Quantification of perilipin-1 WT and 439fs expression levels from 3 independent experiments. Data represented as mean ±SEM. **E)** Stably transfected 3T3-L1 pre-adipocytes expressing WT and 439fs perilipin-1 were grown to confluency and treated with 100 µg/ml cycloheximide and/or 10 µM MG132, 25mM NH₄Cl for 24 hours. Cells were lysed and perilipin-1 and 2 expression levels detected by immunoblotting, β-actin was used to assess loading. A representative image is shown. *-Non-specific band, arrow denotes corresponding band.

**Figure 4. Characterisation of the impact of the perilipin-1 439fs mutant on lipid droplet morphology and lipolysis.**

**A)** Stable cell lines were treated with 400 µM oleic acid for 48 hours, fixed and stained with anti-Myc and anti-mouse-Alexa488 for perilipin-1 (green), LipidTox DeepRed for lipid droplets (red) and DAPI for nuclei (blue); scale bar 10 µm. **B)** Lipid droplet (LD) volume was measured by taking an average of 10 Z-stacks at 63x magnification with 2-3 cells per focal plane, followed by analysis using the Volosity 5 software (Perkin Elmer). Results from three independent experiments are expressed as mean±SEM. **C)** Stable cell lines were loaded with ¹⁴C oleic acid for 16 hours in order to label the intracellular triglyceride pool. Release of incorporated radioactivity was measured over 4 hours in the presence of 6 µM Triascin C to prevent fatty acid re-esterification. Lipolysis is expressed as the percentage of released radioactivity in the medium over total radioactivity incorporated. Results from three
independent experiments are expressed as mean±SEM. In B and C, post hoc pairwise comparisons are shown versus EV and between pairs, indicated with an overlying bar. *** P<0.001 **P<0.01.

**Figure 5. The perilipin-1 439fs mutant interacts with ABHD5 on the surface of lipid droplets.** Interaction between perilipin-1 (wild type (WT), 439fs or 398fs) and ABHD5 was assessed using bimolecular complementation (BiFC) in COS-7 cells after normalizing for equal expression of each protein. A) Yn-ABHD5 and Myc-PLIN1-Yc (wild type (WT), 439fs or 398fs mutants) were co-transfected in COS-7 cells and stained with anti-Myc and anti-mouse-Alexa594 for perilipin-1 (green) and DAPI for nuclei (blue). The presence of YFP BiFC signal indicates direct interaction between perilipin-1 and ABHD5; scale bar 10 µm. B) The YFP BiFC signal was quantified as described in materials and methods. Results from three independent experiments are expressed as mean±SEM, where post hoc comparison is shown vs WT. ns-not significant ** P<0.001. C) The amount of Myc-perilipin-1 and ABHD5 expressed was assessed by immunoblotting. β-actin was used as a loading control.

**Figure 6. The perilipin-1 439fs mutant inhibits the interaction between ATGL and ABHD5.** Interaction between ATGL and ABHD5 was assed using BiFC in COS-7 cells after normalizing for equal expression of each protein. A) Yn-ABHD5, ATGL (S47A)-Yc and myc-PLIN1 (wild type (WT), 439fs or 398fs mutants) were co-transfected in COS-7 cells and stained with anti-Myc and anti-mouse-Alexa594 for perilipin-1 (green) and DAPI for nuclei (blue). The presence of YFP BiFC signal indicates a direct interaction between ATGL and ABHD5; scale bar 10 µm. B) The YFP BiFC signal was quantified as described in materials and methods. Results from three independent experiments are expressed as mean±SEM. Post hoc pairwise comparisons are shown versus EV. ns-not significant ** P<0.001. C)
Expression of Myc-perilipin-1, ABHD5 and ATGL was assessed by immunoblotting. β-actin was used as a loading control.

Figure 7. Characterisation of the consequences of the PLIN1 439fs mutation in pre-adipocytes co-expressing wild type perilipin-1. 3T3-L1 pre-adipocytes stably expressing pLXSN-Flag-PLIN1-WT (wild type) were infected with pBABEpuro EV or Myc-PLIN1 WT, PLIN1 439fs and PLIN1 398fs mutants as described in materials and methods. A) Immunoblot analysis of perilipin-1 expression using an anti-Myc or anti-Flag antibody. β-actin was assessed as a loading control. B) mRNA levels of total hPLIN1 normalized to mCyclophilinA expression. C) Stable cell lines were treated with 400 µM oleic acid for 48 hours, fixed and stained with anti-Myc and anti-mouse-Alexa488 for perilipin-1 (green), LipidTox DeepRed for lipid droplets (red) and DAPI for nuclei (blue); scale bar 10 µm. D) Lipid droplet (LD) volume was measured by taking the average of 10 Z-stacks at 63x magnification with 2-3 cells per focal plane, followed by analysis using Volosity 5 software. Results from three independent experiments are expressed as mean±SEM. E) Stable cell lines were loaded with 14C oleic acid for 16 hours in order to label the intracellular triglyceride pool. Release of incorporated radioactivity was measured over 4 hours in the presence of 6 µM Triascin C to prevent fatty acid re-esterification. Lipolysis is expressed as the percentage of released radioactivity in the media over the total radioactivity incorporated. Results from three independent experiments are expressed as mean±SEM. In D and E, post hoc pairwise comparisons are shown versus EV, and between pairs, indicated with an overlying bar. * P<0.05; **P<0.01; *** P<0.001.
Acanthosis nigricans, hyperinsulinemia or glucose tolerance abnormalities
Lipodystrophy or muscular hypertrophy
Dyslipidemia
Hypertension

Kindred A

Kindred B

Figure 1
**Figure 2**

**A**

![Diagram showing PKA site, Hydrophobic sequence, and Frameshift](image)

**B**

<table>
<thead>
<tr>
<th></th>
<th>Control 1</th>
<th>Control 2</th>
<th>Proband A Visceral</th>
<th>Proband A Leg</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-term Perilipin-1</td>
<td><img src="image" alt="Band" /></td>
<td><img src="image" alt="Band" /></td>
<td><img src="image" alt="Band" /></td>
<td><img src="image" alt="Band" /></td>
</tr>
<tr>
<td>C-term Perilipin-1</td>
<td><img src="image" alt="Band" /></td>
<td><img src="image" alt="Band" /></td>
<td><img src="image" alt="Band" /></td>
<td><img src="image" alt="Band" /></td>
</tr>
<tr>
<td>Perilipin-2</td>
<td><img src="image" alt="Band" /></td>
<td><img src="image" alt="Band" /></td>
<td><img src="image" alt="Band" /></td>
<td><img src="image" alt="Band" /></td>
</tr>
<tr>
<td>Calnexin</td>
<td><img src="image" alt="Band" /></td>
<td><img src="image" alt="Band" /></td>
<td><img src="image" alt="Band" /></td>
<td><img src="image" alt="Band" /></td>
</tr>
</tbody>
</table>
Figure 3

A

perilipin-1

β-Actin

B

hPLIN1 mRNA (AU)

EV WT 439fs 398fs

0

500

1000

1500

2000

EV WT 439fs 398fs

C

CT 6h 12h 24h 32h 48h

WT

439fs

β-Actin

D

% Intensity normalised to CT

WT

439fs

Hours

E

perilipin-2

β-Actin

*
Figure 4

A

DAPI  Perilipin-1  LipidTox  Merge

EV

WT

439fs

398fs

B

LD volume (µm³)

EV  WT  439fs  398fs

C

%14C release normalised to accumulated

EV  WT  439fs  398fs
Figure 5

(A) Panels showing DAPI, BiFC, Perilipin-1, and Merge images for WT, 439fs, and 398fs mutants.

(B) Bar graph showing YFP intensity A.U. for WT, 439fs, and 398fs mutants. The graph indicates a significant decrease in YFP intensity in the 398fs mutant compared to WT and 439fs mutants.

(C) Western blot analysis showing expression levels of Perilipin-1, ABHD5, and β-Actin for WT, 439fs, and 398fs mutants.
Figure 6

(A) DAPI+ Perilipin-1, DAPI+BiFC, Merge

(B) % YFP intensity normalised to positive control

(C) Western blot analysis
Figure 7

A

<table>
<thead>
<tr>
<th>EV+EV</th>
<th>EV+WT</th>
<th>WT+WT</th>
<th>WT+439fs</th>
<th>WT+398fs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myc</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flag</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

hPLIN1 mRNA (AU)

<table>
<thead>
<tr>
<th>EV+EV</th>
<th>EV+WT</th>
<th>WT+WT</th>
<th>WT+439fs</th>
<th>WT+398fs</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>500</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1500</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

DAPI  Flag  Myc  LipidTox  Merge

EV+EV

EV+WT

WT+WT

WT+439fs

WT+398fs

D

LD volume (µm³)

<table>
<thead>
<tr>
<th>EV+EV</th>
<th>EV+WT</th>
<th>WT+WT</th>
<th>WT+439fs</th>
<th>WT+398fs</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

E

%14C release normalised to accumulated

<table>
<thead>
<tr>
<th>EV+EV</th>
<th>EV+WT</th>
<th>WT+WT</th>
<th>WT+439fs</th>
<th>WT+398fs</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proband A</td>
<td>I.2</td>
<td>II.1</td>
<td>II.4</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------</td>
<td>-----</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td><strong>PLIN1 mutation</strong></td>
<td>439fs</td>
<td>439fs</td>
<td>439fs</td>
<td>439fs</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>56</td>
<td>55</td>
<td>38</td>
<td>18</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td>Female</td>
<td>Male</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>31.2</td>
<td>25.4</td>
<td>30.4</td>
<td>29.1</td>
</tr>
<tr>
<td><strong>Fat distribution</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid and femorogluteal lipodystrophy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polycystic ovary syndrome</td>
<td>-</td>
<td>NA</td>
<td>+</td>
<td>NA</td>
</tr>
<tr>
<td>Fatty Liver</td>
<td>+</td>
<td>ND</td>
<td>+</td>
<td>ND</td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cardiomyopathy</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>DEXA FMR</td>
<td>1998-1.4; 2005-1.9</td>
<td>2.2</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Lipodystrophy if FMR&gt;1.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Cholesterol (mmol/L)</td>
<td>10.5</td>
<td>4.6</td>
<td>5.5</td>
<td>4.1</td>
</tr>
<tr>
<td>Triglyceride (mmol/L)</td>
<td>56.1</td>
<td>2</td>
<td>6.1</td>
<td>2.3</td>
</tr>
<tr>
<td>Insulin (pmol/L)</td>
<td>ND</td>
<td>17</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>-----------------</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td>----</td>
</tr>
<tr>
<td>Leptin (ng/mL)</td>
<td>2.9</td>
<td>2.8</td>
<td>3.8</td>
<td>ND</td>
</tr>
</tbody>
</table>

BMI, body mass index; NA, not applicable; ND, not determined; DEXA, dual X-ray absorptiometry; FMR, Fat Mass Ratio (% fat trunk to % fat lower limb ratio);
**Supplementary Figure 1. Clinical photographs of Proband A.**

The images show the distinctive lipodystrophic fat distribution, including retention of truncal fat and fat loss in the limbs and femorogluteal region.

**Supplementary Figure 2. Skin fold thickness measurements in Proband A.**

Measurements were repeated on several occasions, each of which is represented in a different colour (at age 41 years (red), 42 years (yellow), 43 years (green) and 53 years (blue)). Results are expressed as the mean of two independent measurements and compared to previously reported reference ranges 5th percentile and 95th percentile in black line.